Market Intelligence, Clinical Progress, and High-Purity Reagents for Frontotemporal Dementia & Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for Progranulin drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Wild-Type) | Human Progranulin Full-Length Protein High purity (>95%), Endotoxin <0.1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View Progranulin Products |
| Antigen (FTD Mutants) | Progranulin Pathogenic Mutants (R110X, C31LfsX34) For haploinsufficiency modeling. Theoretical MW verified. |
View Progranulin Products |
| Receptor Protein | Sortilin (SORT1) ECD-Fc Fusion For binding/internalization assays. High purity (>95%). |
View Sortilin Products |
| Gene Delivery | Progranulin ORF Lentivirus CMV promoter, Puromycin selection. For stable FTD model cell lines. |
View Progranulin Products |
| Validator | Progranulin siRNA Set (3 unique sequences) For knockdown verification in lysosomal studies. |
View Progranulin Products |
| Benchmark Antibody | Anti-PGRN / Anti-SORT1 (Sequence of latozinemab) Recombinant positive control for assay standardization. |
View Progranulin Products |
| Related Target: Sortilin | Sortilin (SORT1) Essential receptor mediating PGRN lysosomal uptake; target for elevated PGRN strategies. |
View Sortilin Products |
| Related Target: TNFRSF1B | TNF Receptor II (TNFR2) PGRN binding partner for anti-inflammatory signaling modulation. |
View TNFRSF1B Products |
| Related Target: PSAP | Prosaposin (PSAP) Interacts with PGRN for lysosomal trafficking and neuronal survival. |
View PSAP Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| FTD Cross-species Modeling (Human/Mouse/Cyno) | Ortholog Proteins available with >95% purity; Endotoxin <0.1 EU/μg for sensitive neuronal cultures |
| Sortilin Binding Kinetics | SPR-validated binding pairs; Native conformation preservation via HEK293 expression |
| Haploinsufficiency Validation | Pathogenic mutant proteins (R110X, etc.) for loss-of-function mechanistic studies |
| Lysosomal Trafficking Assays | Fluorophore-labeled Progranulin available for uptake/internalization studies |
| Complex Glycosylation & Cleavage | HEK293 Expressed (Native Glycosylation) to ensure proper structural presentation |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization |
Live Progranulin R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active FTD Clinical Trials
- View Active Oncology Trials
- Latest Resistance Research
- Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for Progranulin-targeted therapeutics is intensifying around two opposing mechanistic strategies: PGRN elevation for neurodegeneration (Frontotemporal Dementia) and PGRN inhibition for oncology. In the FTD space, first-generation approaches targeting Sortilin to block PGRN degradation (Alector's AL001, Phase 3) are transitioning toward direct recombinant PGRN replacement and gene therapy (Passage Bio, Prevail Therapeutics). As first-generation biologics reach the clinic, the next wave of R&D is targeting blood-brain barrier penetration enhancement and subcutaneous delivery formulations for chronic neurodegenerative administration, with expanding indications into Alzheimer's Disease and Parkinson's Disease. Gene therapy using AAV vectors (e.g., PBFT02, PR006) aims for long-term PGRN expression, while monoclonal antibodies (latozinemab) offer receptor-blockade strategies with potential in ALS.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Anti-Sortilin mAb | Alector, ARTA Therapeutics | Frontotemporal Dementia, ALS | PGRN/Sortilin binding inhibition assays (Need high-purity ortholog proteins) |
| Recombinant PGRN | Amprion, ARTA Therapeutics | FTD (GRN mutation carriers) | Stability/Viscosity at high concentration (Need endotoxin-controlled protein for ICV/SC models) |
| Gene Therapy (AAV) | Passage Bio, Prevail Therapeutics | FTD-GRN | PGRN expression validation assays (Need overexpression lentivirus controls) |
| PGRN Inhibitors | Preclinical Academic | Solid Tumors | Epitope specificity screening (Need mutant vs WT discrimination) |